Physician profile
Steven M Rodriguez
NPI 1528432135
$3,051.80
in general payments reported to CMS, 2019-2025
14 companies · $918 in 2025
The $918 reported for 2025 was more than what 86% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $864 · 2022: $154 · 2023: $1,116 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,593 · Food and Beverage: $441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,592.99 |
| Food and Beverage | $440.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Cardiovascular Systems Corporation | $1,003.88 | 2023 | Harvest, Virtuosaph Plus With Radial Indication |
| Medical Device Business Services, INC. | $894.50 | 2025 | Evarrest |
| Alnylam Pharmaceuticals INC. | $292.91 | 2021 | |
| Impulse Dynamics (USA) INC. | $179.87 | 2022-2023 | Optimizer |
| Alexion Pharmaceuticals, INC. | $122.08 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $117.61 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.75 | 2021 | |
| Merck Sharp & Dohme LLC | $98.00 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $81.16 | 2021 | |
| Davol INC. | $69.66 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $26.19 | 2021 | |
| Abbott Laboratories | $25.10 | 2021 | |
| Becton, Dickinson and Company | $23.35 | 2025 | Tridyne Vascular Sealant |
| Bayer Healthcare Pharmaceuticals INC. | $17.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.